Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance
Laura Fouassier, Marco Marzioni, Marta B. Afonso, et al.
Liver International (2019) Vol. 39, Iss. S1, pp. 43-62
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesús M. Bañales, José J.G. Marı́n, Ángela Lamarca, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 9, pp. 557-588
Open Access | Times Cited: 1697
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Sara Massironi, Lorenzo Pilla, Alessandra Elvevi, et al.
Cells (2020) Vol. 9, Iss. 3, pp. 688-688
Open Access | Times Cited: 74
Advances in targeted therapy of cholangiocarcinoma
Yuhang Li, Jianfeng Yu, Yujing Zhang, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 12
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis
Serena Mancarella, Grazia Serino, Francesco Dituri, et al.
Cell Death and Differentiation (2020) Vol. 27, Iss. 8, pp. 2330-2343
Open Access | Times Cited: 53
TGFβ-induced long non-coding RNA LINC00313 activates Wnt signaling and promotes cholangiocarcinoma
Panagiotis Papoutsoglou, Raphaël Pineau, Raffaële Leroux, et al.
EMBO Reports (2024) Vol. 25, Iss. 3, pp. 1022-1054
Open Access | Times Cited: 6
Autotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications
Carmelo Laface, Angela Dalia Ricci, Simona Vallarelli, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7737-7737
Open Access | Times Cited: 5
Transforming Growth Factor-Beta (TGFβ) Signaling Pathway in Cholangiocarcinoma
Panagiotis Papoutsoglou, Corentin Louis, Cédric Coulouarn
Cells (2019) Vol. 8, Iss. 9, pp. 960-960
Open Access | Times Cited: 39
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Leticia Colyn, Gloria Álvarez‐Sola, M. Ujúe Latasa, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 19
Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms
Simonetta Lugari, Enrica Baldelli, Amedeo Lonardo
Metabolism and Target Organ Damage (2023) Vol. 3, Iss. 1, pp. 5-5
Open Access | Times Cited: 11
Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
Alice Boilève, Marc Hilmi, Matthieu Delaye, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2708-2708
Open Access | Times Cited: 24
Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
Zhiqing Bai, Zhiying Guo, Jiaxing Liu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
Modulation of STAT3 Signaling, Cell Redox Defenses and Cell Cycle Checkpoints by β-Caryophyllene in Cholangiocarcinoma Cells: Possible Mechanisms Accounting for Doxorubicin Chemosensitization and Chemoprevention
Antonella Di Sotto, Silvia Di Giacomo, Elisabetta Rubini, et al.
Cells (2020) Vol. 9, Iss. 4, pp. 858-858
Open Access | Times Cited: 26
Anticancer Activity of Fucoidan via Apoptosis and Cell Cycle Arrest on Cholangiocarcinoma Cell
Pathanin Chantree, Kesara Na‐Bangchang, Pongsakorn Martviset
Asian Pacific Journal of Cancer Prevention (2021) Vol. 22, Iss. 1, pp. 209-217
Open Access | Times Cited: 19
CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
Serena Mancarella, Grazia Serino, Isabella Gigante, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 13
SerpinB3/4 Expression Is Associated with Poor Prognosis in Patients with Cholangiocarcinoma
Andréa Martini, Kritika Prasai, Tyler Zemla, et al.
Cancers (2024) Vol. 16, Iss. 1, pp. 225-225
Open Access | Times Cited: 2
Huaier inhibits cholangiocarcinoma cells through the twist1/FBP1/Wnt/β-catenin axis
Liyuan Cong, Jian Shi, Jing Zhao, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 2
Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
Christian Mayr, Tobias Kiesslich, Dominik Paul Modest, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 2, pp. 221-233
Closed Access | Times Cited: 12
Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy
Michael Ghio, Adarsh Vijay
Annals of Hepato-Biliary-Pancreatic Surgery (2023) Vol. 27, Iss. 2, pp. 123-130
Open Access | Times Cited: 6
Cholangiocarcinoma: investigations into pathway-targeted therapies
Ioannis Ntanasis‐Stathopoulos, Diamantis I. Tsilimigras, Maria Gavriatopoulou, et al.
Expert Review of Anticancer Therapy (2020) Vol. 20, Iss. 9, pp. 765-773
Closed Access | Times Cited: 16
The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression
Serena Mancarella, Grazia Serino, Sergio Coletta, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4187-4187
Open Access | Times Cited: 10
Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis
Silvia Di Giacomo, Marco Gullì, Roberta Facchinetti, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1264-1264
Open Access | Times Cited: 10
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
Alessandro Rizzo
Medicina (2021) Vol. 57, Iss. 5, pp. 458-458
Open Access | Times Cited: 13
Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy
Leonardo Baiocchi, Keisaku Sato, Burcin Ekser, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 365-375
Open Access | Times Cited: 14
Long Noncoding RNAs in Cholangiocarcinoma
Aude Merdrignac, Panagiotis Papoutsoglou, Cédric Coulouarn
Hepatology (2020) Vol. 73, Iss. 3, pp. 1213-1226
Open Access | Times Cited: 13
A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin‐4 in Tumor Progression
Mickaël Di‐Luoffo, Sophie Pirenne, Thoueiba Saandi, et al.
Hepatology (2021) Vol. 74, Iss. 3, pp. 1445-1460
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top